# ONCY earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ONCY) · [Earnings tab](https://www.lopjlb.com/stock/ONCY?tab=earnings) Updated: 2026-08-14T07:54:05 Quarters analyzed: 8 ## Cross-quarter narrative Across the earnings calls, Oncolytics has made progress in advancing pelareorep toward registrational studies in breast and pancreatic cancer. The company has reported strong clinical data, including final BRACELET-1 data in HR+/HER2- metastatic breast cancer, and has initiated various studies, such as the GOBLET cohorts and a Phase 2 breast cancer study. Management has also emphasized the large addressable market in these indications and has been working to secure partnerships for late-stage development and commercialization. However, the company still faces challenges, including regulatory risks, clinical trial execution, and cash runway uncertainty. ## Latest CallCard · Q1 Oncolytics reports Q1 cash of $15.3M, runway through Q3 2025, positive GOBLET cohort data in anal and pancreatic cancer, derisked breast program, active CEO search, and new $20M equity facility. **Guidance:** vague — Cash runway through Q3 2025; no specific financial guidance provided. **Tone:** mgmt 0.5 · Q&A pressure 0.4 · divergence 0.2 Management highlights positive clinical data across multiple indications, progress in GOBLET cohorts, derisked breast program, and new financing, while acknowledging ongoing CEO search and need for further regulatory discussions. ### Demand visibility Pre-commercial; demand visibility dependent on clinical success and regulatory approval in high unmet need indications. Pelareorep in development for pancreatic, breast, and anal cancers with high unmet medical need; no product revenue; commercial potential tied to registrational study outcomes and partnerships. ### Margins / costs R&D expenses decreased due to lower manufacturing and clinical trial costs; G&A stable. Q1 2025 R&D $4.1M vs $5.7M prior year; G&A $3M consistent; net cash used in operations $6.5M vs $7.5M. ### Capital allocation Capital allocated to clinical development (GOBLET cohorts), CEO search, business development; $20M equity facility extends runway. Cash $15.3M as of March 31, 2025; $20M share purchase agreement with Alumni Capital provides discretionary capital; funds directed to GOBLET milestones, CEO transition, general operations. ### Milestones - **CEO search** [on_track]: Active search, met several excellent candidates, aim to announce new CEO in near future. - **GOBLET Cohort 4 (anal carcinoma)** [on_track]: Interim results: 33% ORR, one complete response >15 months; expanded to Stage 2 enrollment of 18 additional patients. - **GOBLET Cohort 5 (pancreatic cancer)** [on_track]: Safety run-in completed, regulatory permissions received, full enrollment ongoing (>50% of Stage 1 target of 30 evaluable patients); initial efficacy data expected later 2025, public 2026. - **Breast cancer registrational program** [on_track]: Two positive randomized Phase 2 studies (IND-213, BRACELET-1); evaluating registration-enabling study design for accelerated approval, also considering post-ADC and neoadjuvant studies. - **Business development** [on_track]: Encouraging interactions at JPMorgan Conference; upcoming meetings at ASCO and Bio; support from KOLs (Piccart, Eggermont) and advocacy groups (PanCAN). ## Quarter one-liners - **2025 Q1:** Oncolytics reports Q1 cash of $15.3M, runway through Q3 2025, positive GOBLET cohort data in anal and pancreatic cancer, derisked breast program, active CEO search, and new $20M equity facility. - **2024 Q4:** Oncolytics reports $15.9M cash, plans Phase 2 breast cancer study H2 2025 for accelerated approval, shows positive GI cancer data, seeks CEO and BD partners. - **2024 Q3:** Oncolytics reports strong BRACELET-1 final data in HR+/HER2- metastatic breast cancer, plans registration-enabling study for accelerated approval, advances pancreatic cancer programs with GCAR and PanCAN, and prepares for partnering outreach. - **2024 Q2:** Oncolytics advances pelareorep toward registrational studies in breast and pancreatic cancer; FDA Type C meeting aligns on PFS endpoint for breast cancer, BRACELET-1 OS data expected H2 2024, GOBLET cohort 5 dosing initiated with modified FOLFIRINOX, GCAR collaboration progressing for adaptive pancr - **2024 Q1:** Oncolytics advances pelareorep toward registrational studies in breast and pancreatic cancer; FDA Type C meeting Q2, GOBLET expansions, BRACELET-1 OS data H2, $29.6M cash. - **2023 Q4:** Oncolytics reported strong Phase 1/2 data, announced plans for registrational breast and pancreatic trials in 2024, and outlined GOBLET cohort expansions, while analysts probed enrollment timing and OpEx. - **2023 Q3:** Oncolytics reports Q3 2023 progress: pelareorep shows strong pancreatic/colorectal data at ESMO, plans Phase III Precision Promise in 1H2024, $40M cash runway into 2026. - **2023 Q2:** Oncolytics advances pelareorep toward registrational trials in HR+/HER2- breast cancer (BRACELET-1 data) and pancreatic cancer (Precision Promise inclusion), with $15M equity raise funding Phase 3 plans. ## Theme arcs - **Clinical Progress** (improving): Oncolytics has reported strong clinical data and initiated various studies - **Partnership Discussions** (stable): Management has been working to secure partnerships for late-stage development and commercialization - **Regulatory Risks** (deteriorating): Company faces regulatory risks, including FDA alignment on PFS endpoint and overall survival benefit - **Cash Runway** (deteriorating): Cash runway uncertainty, with $15.9M cash as of Dec 31, 2024 - **CEO Search** (stable): CEO search ongoing, creating leadership uncertainty ## Fear persistence - **Regulatory Risk** [recurring]: Company faces regulatory risks, including FDA alignment on PFS endpoint and overall survival benefit - **Clinical Trial Execution** [recurring]: Company faces risks related to clinical trial execution, including enrollment and data readouts - **Cash Runway** [recurring]: Cash runway uncertainty, with $15.9M cash as of Dec 31, 2024 - **Partnership Uncertainty** [recurring]: Company relies on securing partnerships for late-stage development and commercialization, with timing and terms uncertain ## Guidance path 2023 Q2:vague → 2023 Q3:maintained → 2023 Q4:maintained → 2024 Q1:vague → 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/ONCY`